Shoaib Ugradar Selected Research

teprotumumab

3/2022	Thyroid dermopathy responds to teprotumumab therapy.
1/2022	Improvement of asymmetric thyroid eye disease with teprotumumab.
1/2022	Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.
1/2022	Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.
1/2022	Teprotumumab for thyroid eye disease: early response is not required for benefit.
1/2022	A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
1/2022	Teprotumumab for the treatment of chronic thyroid eye disease.
1/2022	Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach.
1/2022	Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
10/2021	Teprotumumab for Asymmetric Thyroid Eye Disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shoaib Ugradar Research Topics

Disease

13	Graves Ophthalmopathy 03/2022 - 01/2018
9	Exophthalmos (Proptosis) 01/2022 - 01/2021
6	Diplopia (Double Vision) 01/2022 - 09/2020
5	Inflammation (Inflammations) 01/2022 - 03/2018
3	Blindness (Hysterical Blindness) 05/2020 - 01/2019
1	Edema (Dropsy) 03/2022
1	Strabismus (Squint) 01/2022
1	Hearing Loss (Hearing Impairment) 01/2022
1	Hyperglycemia 01/2022
1	Optic Nerve Diseases (Optic Neuropathy) 01/2022
1	Spasm (Spasms) 01/2022
1	Body Weight (Weight, Body) 09/2021
1	Congenital Abnormalities (Deformity) 10/2020
1	Enophthalmos 06/2019
1	Rupture 01/2019
1	Retinal Artery Occlusion 01/2019
1	Emphysema 01/2019
1	Immune Reconstitution Inflammatory Syndrome 03/2018

Drug/Important Bio-Agent (IBA)

12	teprotumumabIBA 03/2022 - 01/2021
3	Hyaluronoglucosaminidase (Hyaluronidase)FDA Link 05/2020 - 01/2019
2	Monoclonal AntibodiesIBA 03/2022 - 01/2022
2	Insulin-Like PeptidesIBA 01/2022 - 01/2021
2	Hyaluronic Acid (Hyaluronan)IBA 05/2020 - 01/2019
1	Insulin (Novolin)FDA Link 01/2022
1	Methylprednisolone FDA LinkGeneric 01/2022
1	SteroidsIBA 09/2021
1	Retinaldehyde (Retinal)IBA 10/2020
1	Synthetic Prostaglandins (Prostaglandin Analogues)IBA 06/2019
1	perfluorooctaneIBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2018

Therapy/Procedure

4	Therapeutics 01/2022 - 03/2018
2	Tissue Expansion 03/2022 - 09/2021
1	Blepharoplasty 10/2020
1	Telescopes 09/2020
1	Injections 05/2020
1	Highly Active Antiretroviral Therapy (HAART) 03/2018